. 2020 Mar 2;47(10):2372–2382. doi: 10.1007/s00259-020-04709-x

Table. 1.

Frequency of grade 3 or 4 liver function test abnormalities in the safety population by treatment arm (patients randomised to four cycles of peptide receptor radionuclide therapy with ¹⁷⁷Lu-Dotatate + octreotide LAR 30 mg or octreotide LAR 60 mg) and baseline liver tumour burden (low [< 25%], moderate [25–50%], or high [> 50%]). Liver tumour burden is calculated according to liver tumour volume divided by total liver volume by computed tomography or magnetic resonance imaging

Baseline liver tumour burden	Treatment	No. of Patients	Grade 3 or 4 Liver function test abnormalities, no. of patients
Baseline liver tumour burden	Treatment	No. of Patients	↑ AST	↑ ALT	↑ ALP	↓ Albumin	↑ Bilirubin
<25%	¹⁷⁷Lu-Dotatate + octreotide LAR 30 mg	68	2	3	4	0	1
<25%	Octreotide LAR 60 mg	70	0	0	3	0	0
25–50%	¹⁷⁷Lu-Dotatate + octreotide LAR 30 mg	25	0	0	0	0	1
25–50%	Octreotide LAR 60 mg	12	0	0	0	0	0
>50%	¹⁷⁷Lu-Dotatate + octreotide LAR 30 mg	18	3	1	2	0	0
>50%	Octreotide LAR 60 mg	30	0	0	7	0	0

Data cutoff: 30 June 2016

ALP: alkaline phosphatase, ALT: alanine aminotransferase, AST: aspartate aminotransferase, LAR: long-acting release